Hadden Peter W, Hiscott Paul S, Damato Bertil E
Liverpool Ocular Oncology Centre, St. Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.
Ophthalmology. 2004 Jan;111(1):154-60. doi: 10.1016/j.ophtha.2003.05.007.
To demonstrate the histopathologic features of eyes enucleated after endoresection for choroidal melanoma to assess the complications of this treatment and to determine indications for further treatment after endoresection in the setting of possible tumor recurrence.
Retrospective, observational case series.
Sixty-one consecutive patients who had undergone endoresection for uveal melanoma.
Eyes that had undergone enucleation after endoresection were identified, and their charts and histologic characteristics were reviewed. Pertinent features were described. One patient was excluded because enucleation was performed as a primary treatment when endoresection was abandoned at the time of his initial treatment.
The outcome measures included: reasons for enucleation; tumor recurrence; and location, clinical, and histologic characteristics of each recurrence.
Twelve eyes were identified that had undergone enucleation after endoresection. The reasons for enucleation were: (1) local tumor recurrence detected by ophthalmoscopy (2 patients) or echography (1 patient); (2) opaque media preventing adequate ophthalmoscopy (4 patients); (3) blind and painful eye of uncertain cause (1 patient); and (4) a combination of blind eye and limited fundus view (4 patients), which was the result of untreatable retinal detachment (3 patients) and endophthalmitis (1 patient). Eight of 12 patients had recurrent choroidal melanoma. Recurrences were all located adjacent to the resection site, although in 1 patient there was extensive diffuse recurrence throughout the eye. The recurrence was visible clinically in 3 patients and obscured because of opaque media (2 patients), a combination of inadequate echography and retinal detachment (1 patient), retinal detachment (1 patient), and endophthalmitis (1 patient).
Recurrent disease occurred at the site of the primary tumor with no seeding except in 1 patient, whose marginal recurrence was not immediately detected and treated because of opaque media. As with other treatments conserving the eye, enucleation should be performed if adequate ocular examination is not possible, and follow-up should be lifelong.
展示脉络膜黑色素瘤内切除术后眼球摘除的组织病理学特征,评估该治疗的并发症,并确定在可能出现肿瘤复发情况下内切除术后进一步治疗的指征。
回顾性观察病例系列。
61例连续接受葡萄膜黑色素瘤内切除术的患者。
确定内切除术后接受眼球摘除的眼球,并回顾其病历和组织学特征。描述相关特征。1例患者被排除,因为在其初始治疗时放弃内切除术,眼球摘除作为初始治疗进行。
观察指标包括:眼球摘除的原因;肿瘤复发;每次复发的位置、临床和组织学特征。
确定12只眼球在内切除术后接受了眼球摘除。眼球摘除的原因如下:(1)通过检眼镜检查(2例患者)或超声检查(1例患者)发现局部肿瘤复发;(2)不透明介质妨碍充分的检眼镜检查(4例患者);(3)原因不明的盲眼且疼痛(1例患者);(4)盲眼和眼底视野受限的组合情况(4例患者),这是由无法治疗的视网膜脱离(3例患者)和眼内炎(1例患者)导致的。12例患者中有8例出现复发性脉络膜黑色素瘤。复发均位于切除部位附近,不过有1例患者整个眼球出现广泛弥漫性复发。3例患者的复发在临床上可见,2例因不透明介质而模糊不清,1例因超声检查不充分和视网膜脱离的组合情况,1例因视网膜脱离,1例因眼内炎。
除1例患者外,复发性疾病发生在原发肿瘤部位,无种植转移,该例患者因不透明介质未立即发现并治疗边缘复发。与其他保眼治疗一样,如果无法进行充分的眼部检查,应进行眼球摘除,且应进行终身随访。